Skip to main content

Advertisement

Table 1 Serum IgG antibodies directed to AQP4 and MOG (high-titer MOG-IgG antibodies at ≥ 1:160) in patients with CNS demyelinating diseases

From: Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

Disease Number Females1 Age (y)2 AQP4-IgG1,3 MOG-IgG1,3
NMO 45 41 (91%) * 50 (2-80) 43 (96%) § 3 (7%)
     1,280 2,560
     (40-40,960) (160-2,560)
HR-NMO 53 34 (64%) 48 (13-74) 32 (60%) § 7 (13%)
     1,280 2,560
     (20-20,480) (640-5,120)
ADEM 33 20 (61%) 12 (2-52) § 0 (0%) 14 (42%) §
     - 2,560
      (160-20,480)
CIS 32 22 (69%) 34 (5-57) + 1 (3%) 2 (6%)
     640 (640; 5,120)
MS 71 43 (61%) 40 (14-66) 0 (0%) 2 (3%)
      (160; 160)
CTRL 101 79 (78%) 43 (14-84) 0 (0%) 3 (3%)
      320
      (160-640)
p-value   0.003 < 0.001 < 0.001 < 0.001
  1. P-value: groups were compared using1 Chi-Square test with Fisher's exact post-hoc test and2 Kruskal-Wallis test with Dunn's post-hoc test (data are shown as median with range);3 median titer level (range) of MOG-IgG or AQP4-IgG seropositive samples; * statistically different from HR-NMO, ADEM and MS; + statistically significant from NMO, HR-NMO and ADEM; § statistically significant from all other groups (p-values were corrected for multiple comparisons). Abbreviations: y = years, NMO = Neuromyelitis optica, HR-NMO = High-risk NMO, ADEM = acute disseminated encephalomyelitis, CIS = clinically isolated syndrome, MS = multiple sclerosis, CTRL = controls.